CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Pharma
Original article

TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease

guselkumab
Related Companies

Read the original article

Published by PR Newswire Pharma on October 12, 2026 8:05 PM

Read Original